# Assessing the safety and effectiveness of tocolysis for preterm labour.

No registrations found.

Ethical review	Positive opinion
Status	Pending
Health condition type	-
Study type	Interventional

# **Summary**

# ID

NL-OMON25764

**Source** Nationaal Trial Register

Brief title APOSTEL VIII

#### Health condition

Threatened preterm birth Dreigende vroeggeboorte

# **Sponsors and support**

Primary sponsor: Academic Medical Center P.O. box 22660 1100 DD Amsterdam Tel. 020 - 566 9111 Source(s) of monetary or material Support: ZonMw

### Intervention

#### **Outcome measures**

#### **Primary outcome**

The primary outcome of the study will be a composite adverse perinatal outcome, consisting

of bronchopulmonary dysplasia at 36 weeks postmenstrual age (PMA), periventricular leucomalacia > grade 1, intraventricular hemorrhage > grade 2, necrotizing enterocolitis  $_{i}$ Ý stage 2, retinopathy of prematurity > grade 2 or need for laser therapy, culture proven sepsis and perinatal death.

#### Secondary outcome

Birth within 48 hours, time to delivery, gestational age at delivery, birth weight, number of days on invasive mechanical ventilation, length of admission in NICU, asphyxia, meningitis, pneumothorax and mortality until 3 months corrected age, maternal infection, maternal side effects and costs.

# **Study description**

#### **Background summary**

The Netherlands

Belgium

United Kingdom

Ireland

#### **Study objective**

The aim of this study is to investigate if tocolysis with atosiban in threatened preterm birth (30 to 34 weeks) is (cost-) effective compared with placebo in improving neonatal morbidity and mortality.

#### Study design

Up until 3 months corrected age.

#### Intervention

Atosiban

# Contacts

#### Public

## Scientific

- -

- -
- **Eligibility criteria**

# **Inclusion criteria**

- Woman  $\geq$  18 years old
- Singleton or twin pregnancy
- Gestational age between 30 0/7 and 33 6/7 weeks
- Threatened preterm birth defined by regular uterine contractions and one of the following:
- Cervical length of < 15 mm or

- Cervical length of 15-30 mm and a positive fFn test ( $\geq$  50 ng/mL) or in case of absence of cervical length

measurement in local protocol a positive Fibronectin test or Partus test

- Ruptured amniotic membranes

# **Exclusion criteria**

- Previous treatment for threatened preterm birth with corticosteroids in current pregnancy
- Contra indication for tocolysis
- Signs of fetal distress
- Signs of intra uterine infection
- Fetal chromosomal or severe congenital abnormalities

# Study design

# Design

Study type:Intervention model:Part

Interventional Parallel

Allocation:	Randomized controlled trial
Masking:	Double blinded (masking used)
Control:	Placebo

## Recruitment

NL	
Recruitment status:	Pending
Start date (anticipated):	02-10-2017
Enrollment:	1514
Туре:	Anticipated

## **IPD** sharing statement

Plan to share IPD: Undecided

# **Ethics review**

Positive opinion	
Date:	24-08-2017
Application type:	First submission

# **Study registrations**

# Followed up by the following (possibly more current) registration

ID: 54673 Bron: ToetsingOnline Titel:

# Other (possibly less up-to-date) registrations in this register

No registrations found.

# In other registers

RegisterIDNTR-newNLNTR-oldNT

-<u>-</u> NL6469 NTR6646

Register
ССМО

OMON

**ID** NL61439.018.17 NL-OMON54673

# **Study results**